Neuroscientific Biopharmaceuticals Share Price and Company Fundamentals
Last traded: Today at 4:05 AM
NeuroScientific Biopharmaceuticals Limited engages in the research and development of biomedical products targeting neurodegenerative conditions. Its lead product is the EmtinB drug for the treatment of optic nerve diseases, such as glaucoma. The company also develops StemSmart platform technology to treat inflammatory immune disorders. NeuroScientific Biopharmaceuticals Limited was incorporated in 2002 and is based in Perth, Australia.
Key Metrics
PE ratio
-
PB ratio
2.75
Dividend yield
-
Beta
1.22
Market cap
$46.56M
Enterprise value
$39.29M
Company profile
| Industry / Sector | Biotechnology / Healthcare |
|---|---|
| Website | https://neuroscientific.com |
| Mailing address | 216 St Georges Terrace Level 4 Perth WA 6000 Australia |
| Phone / Fax | 61 8 6268 2641 / |
Dividends
More: Neuroscientific Biopharmaceuticals Dividend history, yield and payout ratio
Dividend yield
-
Dividend amount
$-
Payout ratio
0.00%
5Y Avg. yield
-%
Neuroscientific Biopharmaceuticals paid $- dividend and the ex-dividend date was -.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.NSB dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Feb 2026, following are the company executives and directors listed on Neuroscientific Biopharmaceuticals.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Mr. Nathan Smith | Chief Executive Officer | ||
| Dr. Marian Sturm | Chief Scientific Officer | ||
| Dr. Catherine Cole | Chief Medical Officer | ||
| Mr. Christopher Bryan James Achurch B.Com., C.A. | Company Secretary |
Profitability and management effectiveness
Profit margin
0.00%
Operating margin
-932.60%
Return on assets
-11.21%
Return on equity
-16.65%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Neuroscientific Biopharmaceuticals is 46.56M and its enterprise value is 39.29M. The enterprise value to revenue ratio of NSB is 236.60. The enterprise value to EBITDA ratio of NSB is -20.50.
The NSB's stocks Beta value is 1.22 making it 22% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Neuroscientific Biopharmaceuticals (NSB)
Neuroscientific Biopharmaceuticals (ASX:NSB) Frequently Asked Questions
1. What is Neuroscientific Biopharmaceuticals's Stock Symbol?
Neuroscientific Biopharmaceuticals trades on ASX under the ticker symbol "NSB".
2. What is Neuroscientific Biopharmaceuticals's stock price today?
One share of NSB stock can currently be purchased for approximately $0.14.
3. How can I contact Neuroscientific Biopharmaceuticals?
Neuroscientific Biopharmaceuticals's mailing address is 216 St Georges Terrace Level 4 Perth WA 6000 Australia. The company can be reached via phone at 61 8 6268 2641.
4. What is Neuroscientific Biopharmaceuticals's official website?
The official website of Neuroscientific Biopharmaceuticals is https://neuroscientific.com.